Clinical Trials Browser

Phase 1 × talquetamab × 90 days × Clear all

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT06348108 2026-03-13

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT03399799 2026-03-12

MonumenTAL-1

Phase 1 Active not recruiting

279 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT07093554 2026-01-05

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma